SEARCH

SEARCH BY CITATION

References

  • Ahn, Y.S., Harrington, W.J., Simon, S.R., Mylvaganam, R., Pall, L.M. & So, A.G. (1983) Danazol for the treatment of idiopathic thrombocytopenic purpura. New England Journal of Medicine, 308, 13961399.
  • Ahn, Y.S., Harrington, W.J., Mylvaganam, M., Ayub, J. & Pall, L.M. (1985) Danazol therapy for autoimmune haemolytic anemia. Annals of Internal Medicine, 102, 298301.
  • Barosi, G., Ambrosetti, A., Finelli, G., Grossi, A., Leoni, P., Liberato, N.L., Petti, M.C., Pogliani, E., Ricetti, M., Rupoli, S., Visani, G. & Tura, S. (1999) The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. British Journal of Haematology, 104, 730737.
  • Barosi, G., Grossi, A., Comotti, B., Musto, P., Gamba, G. & Marchetti, M. (2001) Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 114, 7883.
  • Besa, E.C., Nowell, P.C., Geller, N.L. & Gardner, F.H. (1982) Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer, 49, 308313.
  • Brubaker, L.H., Briere, J., Laszlo, J., Kraut, E., Landaw, S.A., Peterson, P., Goldberg, J. & Donovan, P. (1982) Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Archives of Internal Medicine, 142, 15331537.
  • Cervantes, F., Hernández-Boluda, J.C., Alvarez, A., Nadal, E. & Montserrat, E. (2000) Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica, 85, 595599.
  • Cervantes, F., Alvarez-Larrán, A., Hernández-Boluda, J.C., Sureda, A., Torrebadell, M. & Montserrat, E. (2004) Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. British Journal of Haematology, 127, 399403.
  • Chabannon, C., Pegourie, B., Sotto, J.J. & Hollard, D. (1990) Clinical and haematological improvement in a patient receiving danazol therapy for myelofibrosis with myeloid metaplasia. Nouvelle Revue Française d'Hematologie, 32, 165166.
  • Cortes, J., Albitar, M., Thomas, D., Giles, F., Kurzrock, R., Thibault, A., Rackoff, W., Koller, C., O'Brien, S., Garcia-Manero, G., Talpaz, M. & Kantarjian, H. (2003) Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood, 101, 16921697.
  • Giles, F.J., Cooper, M.A., Silverman, L., Karp, J.E., Lancet, J.E., Zangari, M., Shami, P.J., Khan, K.D., Hannah, A.L., Cherrington, J.M., Thomas, D.A., Garcia-Manero, G., Albitar, M., Kantarjian, H.M. & Stopeck, A.T. (2003) Phase II study of SU5416 – a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor – in patients with refractory myeloproliferative diseases. Cancer, 97, 19201928.
  • Hasselbalch, H.C., Clausen, N.T. & Jensen, B.A. (2002) Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin. American Journal of Hematology, 70, 9299.
  • Hast, R., Engstedt, L., Jameson, S., Killander, A., Lundh, B., Reizenstein, P., Skarberg, K.O., Uden, A.M. & Wadman, B. (1978) Oxymetholone treatment in myelofibrosis. Blut, 37, 1926.
  • Jacobson, R.J., Salo, A. & Fialkow, P.J. (1978) Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood, 51, 189194.
  • Kennedy, B.J. (1962) Effect of androgenic hormone in myelofibrosis. JAMA, 182, 114119.
  • Lennert, K., Naghai, K. & Schwarze, E.W. (1975) Patho-anatomical features of the bone marrow. Clinics in Haematology, 43, 331351.
  • Levy, V., Bourgarit, A., Delmer, A., Legrand, O., Baudard, M., Rio, B. & Zittoun, R. (1996) Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases. American Journal of Hematology, 53, 239241.
  • Mesa, R.A., Steensma, D.P., Pardanani, A., Li, C.Y., Elliott, M., Kaufmann, S.H., Wiseman, G., Gray, L.A., Schroeder, G., Reeder, T., Zeldis, J.B. & Tefferi, A. (2003) A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood, 101, 25342541.
  • Reilly, J.T. (1998) Pathogenesis and management of idiopathic myelofibrosis. Baillière's Clinical Hematology, 11, 751767.
  • Silver, R.T., Jenkins, Jr, D.E. & Engle, R.L. (1964) Use of testosterone and busulfan in the treatment of myelofibrosis with myeloid metaplasia. Blood, 23, 341353.
  • Stadtmauer, E.A., Cassileth, P.A., Edelstein, M., Abrahm, J., Schreiber, A.D., Nowell, P.C. & Cines, D.B. (1991) Danazol treatment of myelodysplastic syndromes. British Journal of Haematology, 77, 502508.